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ABSTRACT 
 
The aim of this study was to validate the partial agonistic property of two natural isolated β2-adrenocepotor 
agonists using rat uteri in vitro functional efficacy test. Our results revealed that the combination of the two 
agonists exhibited intermediate relaxing effect represented as dose-response curve with 50% Emax of terbutaline, 
which confirmed by the effect of the selective β2-adrenoceptors antagonist ICI118.551, and their significant 
inhibition of terbutaline relaxing effect in both uteri. Finally, both isolated compounds are considered as partial β2-
adrenoceptors agonists. 
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INTRODUCTION 
 
Partial agonists were of therapeutic essentials [1-2-3-4], the β-adrenergic partial agonist; alifedrine was implicated in 
the management of cardiac performance with acute ischemic left ventricular failure [1]. 
 
In our previous studies, we isolates two compound from El-hazha herb, 6-methoxykaempferol-3-O-glucoside (6-
MKG) [2] and Haplopine-3,3'-dimethylallyl ether (HAP) [3] and investigated their β2-Adrenoceptors activity, but 
we observed that their activities were less than that of  terbutaline [4]. These observations encourage us to think 
about their partial property which was not studied yet. This study aimed to validate this partial activity for both 
compounds.  
 
EXPERIMENTAL SECTION 
 
In vitro functional efficacy test  
Ethical considerations for housing and handling the animals 
The animals were treated in accordance with the European Communities Council Directives (86/609/ECC) and the 
Hungarian Act for the Protection of Animals in Research (XXVIII.tv.32. §). All experiments involving animal 
subjects were carried out with the approval of the Hungarian Ethical Committee for Animal Research (registration 
number: IV/1758-2/2008). Sprague-Dawley rats (Charles-River Laboratories, Hungary) were kept at 22 ± 3 oC; the 
relative humidity was 30-70% and the light/dark cycle was 12/12 h. They were maintained on a standard rodent 
pellet diet (Charles-River Laboratories, Hungary), with tap water available ad libitum. The animals were sacrificed 
by CO2 inhalation. 
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Uterus preparation 
Uteri were removed from non-pregnant rats (180–200 g) and on pregnancy day 22 from pregnant rats (270–350 g). 
Muscle rings 5 mm long were sliced from the uterine horns and mounted vertically in an organ bath containing 10 
ml de Jongh solution (composition: 137 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 4 mM 
NaH2PO4, 6 mM glucose, pH=7.4). The organ bath was maintained at 37 °C and carbogen (95% O2+5% CO2) was 
bubbled through it. After mounting, the rings were equilibrated for about 1 h before the experiments were 
undertaken; with a solution change every 15 min. The initial tension of the preparation was set to about 1.5 g, which 
was relaxed to about 0.5 g at the end of equilibration. The tension of the myometrial rings was measured with a 
gauge transducer (SG-02; Experimetria Ltd., Budapest, Hungary) and recorded with a SPEL Advanced ISOSYS 
Data Acquisition System (Experimetria Ltd., Budapest, Hungary). 
 
Uteri were pre-contracted with 25 mM KCl and cumulative concentration–response curves were constructed in each 
experiment for both compound together alone, and then everyone alone with terbutaline on isolated tissue and 
together with terbutaline in different concentrations (range from 10-9 to 10-4 M) in the presence or absence of 3-
(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol (ICI 118,551) (10-5 M). Following the addition of each 
concentration of the tested material, recording was performed for 5 min. Area under the curve were evaluated and 
concentration–response curves were fitted; Emax, EC50 and pA2 values were determined and compared statistically by 
using the computer program Prism 5.0. (GraphPad Software, USA). 
 
RESULTS AND DISCUSSION 
 
6-MKG and HAP alone and together produce intermediate curves on non-pregnant (Fig. 1A) and late-pregnant (Fig. 
1B) rat uteri, compared to that of terbutaline. 
 
The calculated pA2 values that indicate affinity of combination of 6-KMG and  HAP and standard terbutaline 
standard with the selective β2-adrenoceptors antagonist ICI118.551 in a dose of [10-9M and 10-4 M] for at least six 
repeated measures were showed in a tabular form (Table 1). 
 
Addition of 6-KMG and  HAP to terbutaline decreased significantly its effect and shifted its dose-response curve to 
the right in NP and LP rat uteri (Fig. 2). 
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Fig. 1: Dose-response curves of the relaxing effect of terbutaline, 6-MKG, HAP and their combination on non-pregnant (A) and late-
pregnant (B) rat uteri in vitro, pre-contracted with 25 mM KCl 
Values presented are means of 6-8 observations; vertical bars denote standard errors of the mean (S.E.M.). , *, P<0.05, for HAP against 
terbutaline 
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Fig. 2:  Dose-response curves of the effect of HAP+ terbutaline (dotted-line) and terbutaline + 6-MKG (continuous-line) on non-pregnant 
(A) and late-pregnant (B) rat uterus in vitro against KCl-induced control contractions 
Values presented are means of 6-8 observations, while vertical bars denote standard errors of the mean (SEM), *, P<0.05, for HAP against 
terbutaline 
 
Table 1: Effect of ICI118,551 on the relaxing activities of  combination of 6-MKG and HAP on non-pregnant and late pregnant rat uteri 
in vitro 
 
Rat uterus          pA2 [mean ± SEM], N=8                                   Emax [mean ± SEM]%, N=8 
    without ICI with ICI 
Non-pregnant 6.8 ± 0.6   51.5 ± 5.5 35.7 ± 2.6  
Late-pregnant 6.0 ± 0.5a   38.8  ± 1.6 27.4 ± 2.1 
pA2: negative logarithm of the competitive antagonist concentration at which the agonist concentration should be doubled to reach the same 
effect that without the antagonist; N: total number of observations; ICI: ICI18,551 a: p>0.05, ns: not significant. 
 
Literature survey revealed that, there is increasing importance of natural products in the areas of drug discovery [5]. 
Although information regarding the binding sites of partial agonists is still not sufficient to explain why they cannot 
fully activate the receptor, partial agonists still were of therapeutic essentials [6-7-8-9-10-11].  
 
This study serves as functional efficacy test or pharmacodynamic drug-drug interactions of two isolated compounds 
that possesses β2-Adrenoceptors agonist activity [2-3]   
 
The resulted intermediate curve of combination was in line with our hypothesis, indicating the partial feature for 6-
MKG against the HAP, whilst the combination effect regard terbutaline.  
 
The total combination maximum effect was approximately 50% which represent atypical partial agonist property 
[12], because partial agonist is a compound that can activate receptors but is unable to elicit the maximal response of 
the receptor system.  
 
These findings were confirmed by the ICI effects on combination comparable to terbutaline, which can be taken as 
an evidence regard the partial agonistic feature of our compounds. 
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